Filing status
- Accounts due
- 30 September 2027
- Last accounts
- 31 December 2025
- Conf. stmt due
- 17 June 2027
- Last conf. stmt
- 3 June 2026
Dark Blue Therapeutics Ltd
- Incorporated
- 4 June 2020 (6 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Owned by
- Accounts type
- Small
- Region
- South East
- Address
- Hayakawa BuildingEdmund Halley RoadThe Oxford Science ParkOxfordOX4 4GB
Officers 2 active
Officer details are public data from the Companies House register.
British
Born November 1966
Director · Appointed 30 December 2025
Also at Amgen Limited, Kleidox Therapeutics Ltd (proposed for strike-off)
British
Born January 1975 (51)
Officer history (13 former)
3 July 2026
8 June 2026
30 December 2025
Resigned Smith, Emma as Secretary
30 December 2025
30 December 2025
Resigned Moses, Edwin, Dr as Director
30 December 2025
30 December 2025
30 December 2025
30 December 2025
30 December 2025
Resigned Carmichael, James, Dr as Director
17 March 2025
Appointed Moses, Edwin, Dr as Director
16 May 2024
16 May 2024
9 March 2023
Appointed Smith, Emma as Secretary
8 August 2022
18 June 2022
18 June 2022
18 June 2022
23 October 2020
23 October 2020
21 August 2020
21 August 2020
24 July 2020
24 July 2020
24 July 2020
Appointed Carmichael, James, Dr as Director
24 July 2020
24 July 2020
4 June 2020
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 30 December 2025
Owns 75–100% of shares
Holds 75–100% of voting rights
Right to appoint and remove directors
Private Company Limited By Shares
Reg. no. 16897338
Former controllers (5)
30 December 2025
Ceased Oxford Science Enterprises PLC — Owns 25–50% of shares
30 December 2025
Ceased BMS Strategic Portfolio Investments Holdings, Inc. — Owns 25–50% of shares
28 June 2024
Ceased Evotec International GMBH — Owns 25–50% of shares
17 October 2022
Ceased Oxford Science Enterprises PLC — Owns 25–50% of shares
24 July 2020
Group structure 4 companies
Ownership group derived from the Companies House PSC register
Dark Blue Therapeutics Ltd This company Owns 75–100% of shares
Sandymount Therapeutics Ltd Owns 75–100% of shares
Filings
Filing history not loaded yet. See it on Companies House
Other companies in this industry
By trade and location
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →